Peritoneal Carcinomatosis: Current State of the Art and Schools of Thought
https://doi.org/10.24060/2076-3093-2021-11-1-85-91
Abstract
Peritoneal carcinomatosis (PC) is a global challenge of modern oncology representing the most unfavourable scenario in diverse-locality tumourisation. Despite certain attention by the oncological community, the management of PC patients is currently palliative, which weakly promotes research into the basic principles of this morbidity. This literature review attempts to comprehensively cover the PC problematic from a global perspective and presents a key evidence on the world schools of thought in this area. Briefly taking, peritoneal carcinomatosis is viewed today as a local process in the conventional implantation theory, which imposes a locoregional character on all current or emerging therapies, such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Their inadequate efficacy is largely due to pronounced gaps in our understanding of PC logistics and signalling. PSOGI is a key organisation for centralising the specialty effort in peritoneal carcinomatosis. Despite its global geography and approach to PC discussion, a multitude of scientific questions remain unanswered impeding the establishment of novel effective therapies. The seven countries that nurtured distinguished schools of thought in PC studies are the USA, UK, Japan, China, Italy, France and Germany. Taking peritoneal carcinomatosis in a global perspective, an insufficient attention to its problematic in Russia should be addressed. The founding and fostering of national PC institutions will benefit cancer patients and progress in oncological science.
About the Authors
Sh. Kh. Gantsev
Bashkir State Medical University
Russian Federation
Russian Federation
Shamil Kh. Gantsev — Dr. Sci. (Med.), Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education
Ufa
M. V. Zabelin
Ministry of Health of the Republic of Bashkortostan
Russian Federation
Russian Federation
Maksim V. Zabelin — Dr. Sci. (Med.), Deputy Prime Minister of the Government of the Republic of Bashkortostan, Minister of Health of the Republic of Bashkortostan
Ufa
K. Sh. Gantsev
Bashkir State Medical University
Russian Federation
Russian Federation
Kamil Sh. Gantsev — Dr. Sci. (Med.), Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education
Ufa
A. A. Izmailov
Bashkir State Medical University
Russian Federation
Russian Federation
Adel A. Izmailov — Dr. Sci. (Med.), Assoc. Prof., Department of Urology with a course of Advanced Professional Education
Ufa
Sh. R. Kzyrgalin
Bashkir State Medical University
Russian Federation
Russian Federation
Shamil R. Kzyrgalin — Cand. Sci. (Med.), Assoc. Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education
Ufa
References
1. Gantsev S.K., Solomenny S.V., Gantsev K.S., Kzyrgalin S.R., Minigazimov R.S., Loginova M.V. Assessment of serous lymph hatches in peritoneal carcinomatosis (diaphragmatic peritoneum) by scanning electron microscopy. Creative surgery and oncology. 2014;(4):4–10 (In Russ.). DOI: 10.24060/2076-3093-2014-0-4-4-10
2. Sugarbaker P.H., Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58(2):96–107. DOI: 10.1159/000012086
3. Cotte E., Passot G., Gilly F.N., Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. 2010;2(1):31–5. DOI: 10.4251/wjgo.v2.i1.31
4. Sadeghi B., Arvieux C., Glehen O., Beaujard A.C., Rivoire M., Baulieux J., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. DOI: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o
5. European School of Peritoneal Surface Oncology (ESPSO) [cited 2020 Dec 20]. Available from:http://www.essoweb.org/school-of-peritonealsurface-oncology-es/
6. Sugarbaker P.H., Chang D., Koslowe P. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:89–104. DOI: 10.1007/978-1-4613-1245-1_9
7. Sugarbaker P.H., Stuart O.A. Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series. Surg Oncol. 2020;33:96–9. DOI: 10.1016/j.suronc.2020.01.009
8. Sugarbaker P.H. Intraperitoneal delivery of chemotherapeutic agents for the treatment ofperitoneal metastases: current challenges and how to overcome them. Expert Opin Drug Deliv. 2019;16(12):1393–401. DOI: 10.1080/17425247.2019.1693997
9. Carr N.J., Bibeau F., Bradley R.F., Dartigues P., Feakins R.M., Geisinger K.R., et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71(6):847–58. DOI: 10.1111/his.13324
10. Nors J., Funder J.A., Swain D.R., Verwaal V.J., Cecil T., Laurberg S., et al. Postoperative paralytic ileus after cytoreductive surgery combined with heated intraperitoneal chemotherapy. Pleura Peritoneum. 2019;5(1):20190026. DOI: 10.1515/pp-2019-0026
11. Farquharson M., Hollingshead J., Brendan M. (eds). Farquharson’s Textbook of Operative General Surgery. 10th ed. CRC Press; 2014.
12. Brendan M., Heald R.J. (editors) Manual of Total Mesorectal Excision. CRC Press; 2013.
13. Canbay E., Yonemura Y. Peritoneal Surface Malignancies: A Curative Approach. 10th ed. Springer; 2015.
14. Ji Z.H., Peng K.W., Yu Y., Li X.B., Yonemura Y., Liu Y., et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017;33(5):562–70. DOI: 10.1080/02656736.2017.1283065
15. Coccolini F., Nardi M., Montori G., Ceresoli M., Celotti A., Cascinu S., et al. Neoadjuvant chemotherapyin advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018;51:120–7. DOI: 10.1016/j.ijsu.2018.01.008
16. Lin Y.L., Zhang J., Yan F.C., Jiang X., Ma R., Yang Z.R., et al. Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil. Cancer Med. 2020;9(3):1104–14. DOI:10.1002/cam4.2766
17. Yang X.J., Huang C.Q., Suo T., Mei L.J., Yang GL., Cheng F.L., et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81. DOI: 10.1245/s10434-011-1631-5
18. Huang C.Q., Min Y., Wang S.Y., Yang X.J., Liu Y., Xiong B., et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of currentevidence. Oncotarget. 2017;8(33):55657–83. DOI: 10.18632/oncotarget.17497
19. Guadagni S., Clementi M., Masedu F., Fiorentini G., Sarti D., Deraco M., et al. A pilot study of the predictive potential of chemosensitivity and gene expression assays using circulating tumour cells from patients with recurrent ovarian cancer. Int J Mol Sci. 2020;21(13):4813. DOI: 10.3390/ijms21134813
20. Belfiore A., Busico A., Bozzi F., Brich S., Dallera E., Conca E., et al. Molecular signatures for combined targeted treatments in diffuse malignant peritoneal mesothelioma. Int J Mol Sci. 2019;20(22):5817. DOI: 10.3390/ijms20225817
21. Glehen O., Gilly F.N. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12(3):649–71. DOI: 10.1016/s1055-3207(03)00037-1
22. Alyami M., Hübner M., Grass F., Bakrin N., Villeneuve L., Laplace N., et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–77. DOI:10.1016/S1470-2045(19)30318-3
23. Glehen O., Osinsky D., Beaujard A.C., Gilly F.N. Natural history of peritoneal carcinomatosis from non gynecologic malignancies. Surg Oncol Clin N Am. 2003;12(3):729–39, XIII. DOI: 10.1016/s1055-3207(03)00044-9
24. Glehen O., Gilly F.N., Cotte E. Hyperthermic intraperitoneal chemotherapy in advanced gastric cancer: the end of skepticism? Ann Surg Oncol. 2011;18(6):1524–6. DOI: 10.1245/s10434-011-1632-4
25. Rau B., Brandl A., Piso P., Pelz J., Busch P., Demtröder C., et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23(1):11–22. DOI: 10.1007/s10120-019-00978-0
26. Vassos N., Piso P. Metastatic colorectal cancer to the peritoneum: current treatment options. Curr Treat Options Oncol. 2018;19(10):49. DOI: 10.1007/s11864-018-0563-8
Review
For citations:
Gantsev Sh.Kh., Zabelin M.V., Gantsev K.Sh., Izmailov A.A., Kzyrgalin Sh.R. Peritoneal Carcinomatosis: Current State of the Art and Schools of Thought. Creative surgery and oncology. 2021;11(1):85-91. (In Russ.) https://doi.org/10.24060/2076-3093-2021-11-1-85-91
Views:
1933
Email this article 